NASDAQ:LMDX LumiraDx (LMDX) Stock Price, News & Analysis → Fidelity, Bezos, Goldman Bet Big on Tiny Biotech (From Behind the Markets) (Ad) Free LMDX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.0076▼$0.016052-Week Range N/AVolume132.24 million shsAverage Volume56.75 million shsMarket Capitalization$5.10 millionP/E RatioN/ADividend YieldN/APrice Target$1.75 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestSocial Media Get LumiraDx alerts: Email Address Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About LumiraDx Stock (NASDAQ:LMDX)LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.Read More Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. LMDX Stock News HeadlinesApril 14, 2024 | morningstar.comLumiraDx Ltd LMDXFJanuary 31, 2024 | reuters.comLMDX.OMay 8, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. January 8, 2024 | msn.comWhy LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving PremarketJanuary 8, 2024 | investorplace.comWhy Is LumiraDx (LMDX) Stock Down 13% Today?January 5, 2024 | finance.yahoo.comLumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9thJanuary 2, 2024 | msn.comRoche (RHHBY) to Acquire LumiraDx's Point of Care TechnologyJanuary 2, 2024 | benzinga.comRoche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295MMay 8, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. January 2, 2024 | benzinga.comWhy LumiraDx Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving PremarketJanuary 2, 2024 | msn.comLumiraDx falls on agreement with Roche to sell assetsDecember 29, 2023 | reuters.comRoche to buy part of LumiraDx diagnostics platform for $295 millionDecember 29, 2023 | finanznachrichten.deLumiraDx Inc: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to RocheDecember 29, 2023 | finance.yahoo.comRoche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platformDecember 29, 2023 | markets.businessinsider.comLumiraDx Agrees To Sell Point-of-Care Tech Platform To RocheDecember 29, 2023 | finance.yahoo.comLumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to RocheDecember 29, 2023 | finance.yahoo.comLumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to RocheDecember 26, 2023 | uk.finance.yahoo.comLumiraDx Limited (LMDX)November 27, 2023 | msn.comLumiraDx (LMDX) Price Target Increased by 12.50% to 1.22November 15, 2023 | morningstar.comLumiraDx Ltd LMDXNovember 2, 2023 | benzinga.comWhy Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving PremarketOctober 31, 2023 | benzinga.comWhy Pinterest Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving PremarketOctober 28, 2023 | finanznachrichten.deLumiraDx Inc: LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to AppealOctober 27, 2023 | finance.yahoo.comLumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to AppealOctober 24, 2023 | msn.comWhy Is LumiraDx (LMDX) Stock Down 35% Today?October 20, 2023 | finanznachrichten.deLumiraDx Inc: LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England's First Heart & Lung Screening HubSeptember 27, 2023 | finance.yahoo.comLumiraDx Limited (LMDX) Loses -25.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerSee More Headlines Receive LMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/24/2023Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LMDX CUSIPN/A CIK1685428 Webwww.lumiradx.com Phone354-640-0540FaxN/AEmployees1,210Year FoundedN/APrice Target and Rating Average Stock Price Target$1.75 High Stock Price Target$2.70 Low Stock Price Target$0.80 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-447,790,000.00 Net Margins-268.45% Pretax Margin-264.58% Return on EquityN/A Return on Assets-77.91% Debt Debt-to-Equity RatioN/A Current Ratio0.45 Quick Ratio0.23 Sales & Book Value Annual Sales$126.52 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.33) per share Price / BookN/AMiscellaneous Outstanding Shares318,546,000Free Float205,749,000Market Cap$5.10 million OptionableNot Optionable Beta1.73 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMs. Veronique Ameye EMBA (Age 46)Esq., M.B.A., CEO & General Counsel Mr. Dorian LeBlanc CPA (Age 48)CFO & VP of Global Operations Ms. Colleen McMillenVice President of CommunicationsAndy WardNational Sales Director - UKMr. David Walton DMS (Age 69)Chief Commercial Officer Giffin DaughtridgePresident of North America Commercial Operations & Global Molecular SolutionsMelissa GarciaVP & Corporate CounselMore ExecutivesKey CompetitorsSynaptogenixNASDAQ:SNPXGenprexNASDAQ:GNPXNexImmuneNASDAQ:NEXISeelos TherapeuticsNASDAQ:SEELZyVersa TherapeuticsNASDAQ:ZVSAView All CompetitorsInstitutional OwnershipSenvest Management LLCSold 2,522,037 shares on 2/12/2024Ownership: 2.534%View All Institutional Transactions LMDX Stock Analysis - Frequently Asked Questions Should I buy or sell LumiraDx stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LumiraDx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LMDX shares. View LMDX analyst ratings or view top-rated stocks. What is LumiraDx's stock price target for 2024? 1 Wall Street research analysts have issued twelve-month target prices for LumiraDx's stock. Their LMDX share price targets range from $0.80 to $2.70. On average, they anticipate the company's stock price to reach $1.75 in the next year. View analysts price targets for LMDX or view top-rated stocks among Wall Street analysts. How were LumiraDx's earnings last quarter? LumiraDx Limited (NASDAQ:LMDX) issued its quarterly earnings results on Thursday, August, 24th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01. The business earned $21 million during the quarter, compared to analyst estimates of $21.07 million. During the same quarter in the previous year, the business posted ($0.58) earnings per share. This page (NASDAQ:LMDX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsWatch this FREE trading tutorial while it’s still availableInvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LumiraDx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
